Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.78
28.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Jiangsu Nhwa Pharmaceutical Co Ltd
Research & Development
Jiangsu Nhwa Pharmaceutical Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
|
Research & Development
-ÂĄ672.7m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Research & Development
-ÂĄ2.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Research & Development
-ÂĄ305m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Research & Development
-ÂĄ7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Research & Development
-ÂĄ356.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Research & Development
-ÂĄ1.4B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
Glance View
Jiangsu Nhwa Pharmaceutical Co., Ltd. is an intriguing player in the pharmaceutical industry, operating with a robust focus on innovative therapeutic solutions. Headquartered in the bustling economic landscape of China, the company has carved a niche for itself primarily in the central nervous system (CNS) sector. Nhwa Pharmaceutical leverages advanced research and development to craft medications aimed at treating a variety of CNS disorders, including depression, schizophrenia, and epilepsy. This specialization in a highly complex and demanding field underscores the company's commitment to addressing some of the most challenging health issues faced by modern society. By advancing its expertise in this area, Nhwa ensures a steady stream of cutting-edge products that form the backbone of its revenue. The company's financial model strongly revolves around the development and commercialization of high-demand medications. Nhwa's revenues are primarily derived from domestic and international sales of its pharmaceuticals. It also invests considerably in maintaining a pipeline of products that are either in the development or regulatory approval stages. This strategic focus on a balanced product portfolio enables Nhwa to remain resilient against market fluctuations. Their investments in research are complemented by collaborations with academic institutions and other pharmaceutical enterprises, further amplifying their reach and competitiveness. This formula allows Nhwa Pharmaceutical to not only capture significant market share but also contribute meaningfully to the ongoing evolution of medical treatments in its chosen specialties.
See Also
What is Jiangsu Nhwa Pharmaceutical Co Ltd's Research & Development?
Research & Development
-672.7m
CNY
Based on the financial report for Sep 30, 2025, Jiangsu Nhwa Pharmaceutical Co Ltd's Research & Development amounts to -672.7m CNY.
What is Jiangsu Nhwa Pharmaceutical Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-23%
Over the last year, the Research & Development growth was -12%. The average annual Research & Development growth rates for Jiangsu Nhwa Pharmaceutical Co Ltd have been -18% over the past three years , -23% over the past five years .